ClinicalTrials.gg
Not yet recruitingNCT07601698Updated May 22, 2026

Dexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia

A Phase 4 interventional study of Dexmedetomidine and Propofol in Emergence Agitation, sponsored by Sohag University. Not yet recruiting. Open to participants aged 2 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Sohag University · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
2 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.

Planned enrollment
20th of 83
200 · median 100
Started
2026
with 15 others
Phase 4
31 of 83
10 open now
Primary completion
2026-11
later than 14 of 31 live
Registered
78th of 83
by date

Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 20th largest by planned enrollment, is one of 16 that started in 2026, is one of 31 in phase 4, reaches primary completion later than 14 of the 31 other live ones, and was the 78th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 2 Years to 8 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing dexmedetomidine in Emergence Delirium, or all of them as a file.
02

Study summary

Primary we will Compare the Efficacy between Dexmedetomidine and "Propofol-lidocaine" mixture in preventing the post operative emergence agitation following sevoflurane anasthesia in pediatric ophthalmic surgeries Secondary we will evaluate time of extubation, time of orientation, Hemodynamic variables, Visual analog scale ( VAS), facial expressions scale , Adverse events

Read the detailed description

Emergence agitation (EA) is a frequent and distressing complication in pediatric anesthesia, particularly following the use of volatile agents such as sevoflurane. It is characterized by restlessness, inconsolable crying, disorientation, and incongruent behavior during the early recovery period from general anesthesia (Dahmani S et al.,2014 ). Although EA is usually self-limited, it may cause harm to patients by leading to self-injury, disruption of surgical sites, removal of intravenous lines, or increased stress for caregivers and healthcare providers. The reported incidence of EA in children ranges between 10% and 80%, with higher prevalence observed in younger patients and in ophthalmic surgeries due to sensory deprivation and postoperative discomfort (Dahmani S et al.,2014 ). Sevoflurane remains the most widely used inhalational agent in pediatric anesthesia because of its rapid induction, low airway irritability, and favorable hemodynamic profile. However, it has been consistently associated with a higher risk of EA compared with other anesthetic techniques (Zhang Y et al., 2022) - (Liu J et al., 2022). Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, has emerged as a promising agent due to its sedative, analgesic, and anxiolytic properties without significant respiratory depression (Zhang Y et al., 2022) - (Liu J et al., 2022). Several studies have demonstrated its efficacy in reducing the incidence and severity of EA when administered perioperatively (Zhang Y et al., 2022)- (Abdel-Ghaffar HS et al., 2019). On the other hand, propofol, a short-acting intravenous anesthetic with sedative and antiemetic properties, has also been investigated for EA prevention. When combined with lidocaine, propofol infusion provides not only smooth sedation and rapid recovery but also decreases pain associated with injection and potentially modulates airway reflexes and emergence agitation (Kim YH et al., 2014). Previous studies have shown that a single bolus dose of propofol at the end of surgery can reduce EA incidence in children undergoing ophthalmic surgery (Aouad MT t al., 2007). Meta-analyses further confirmed the beneficial role of propofol in reducing EA and improving recovery profiles (Liu J et al.,2022) -(Li Y et al.,2019). In ophthalmic surgeries for young children, smooth emergence from anesthesia is crucial, as agitation can compromise surgical outcomes, increase the risk of complications, and delay recovery (Kim YH et al., 2014)- (Aouad MT t al., 2007).

03

Conditions studied

  • Emergence Agitation

Browse trials for

Keywords

  • EA
04

Who can participate

Ages eligible
2 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients aged 2-8 years .
  • I-II.
  • Scheduled for elective surgeries under general anesthesia with sevoflurane

Exclusion criteria

Exclusion Criteria:

  • History of psychiatric illness or cognitive impairment.
  • Known allergy to study drugs.
  • Severe cardiovascular, hepatic, or renal disease.
  • Chronic use of sedatives or opioids.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    dexmedetomidine

    Dexmedetomidine 0.3mcg /kg over diluted in 10 ml 0.9% Na cl over 10 min and 10 min before end of surgery

    Drug: Dexmedetomidine

  • Experimental
    Propofol plus lidocaine

    Propofol 2mg/kg plus lidocaine 1mg/kg over 10 min and 10 min before end of surgery

    Drug: Propofol

  • Placebo comparator
    placebo

    receive placebo 10 ml 0.9% Nacl over 10 min and 10 min before end of surgery

    Drug: Placebo

Interventions

  • Dexmedetomidine 0.3mcg /kg over diluted in 10 ml 0.9% Na cl over 10 min and 10 min before end of surgery

  • Propofol 2mg/kg plus lidocaine 1mg/kg over 10 min and 10 min before end of surgery.

  • DrugPlacebo

    receive placebo 10 ml 0.9% Nacl over 10 min and 10 min before end of surgery

06

What researchers measure

Primary outcomes

  1. Incidence of emergence agitation

    Incidence of emergence agitation assessed using Aono's Four-Point Scale after extubation in pediatric patients undergoing ophthalmic surgery under sevoflurane anesthesia.

    Time frame: Assessed at 5, 10, 15, and 30 minutes after extubation in the post-anesthesia care unit (PACU)

Secondary outcomes

  1. Time to extubation

    The interval between discontinuation of anesthetic agents and successful extubation.

    Time frame: From discontinuation of anesthesia until extubation, up to 30 minutes

  2. Time to orientation

    The interval between discontinuation of anesthetic agents and recovery of adequate consciousness to follow simple commands.

    Time frame: During recovery period in PACU, up to 30 minutes postoperatively

  3. Hemodynamic variables

    Assessment of heart rate during emergence and recovery period.

    Time frame: From baseline until 30 minutes postoperatively

  4. Postoperative pain score

    Assessment of postoperative pain using Wong-Baker FACES scale according to patient age.

    Time frame: During the first 4 postoperative hours

  5. Adverse events

    Incidence of adverse events including bradycardia, hypotension, nausea, vomiting, respiratory depression, and postoperative nausea and vomiting.

    Time frame: During surgery and within the first 24 postoperative hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Nov 2026, 6 months later.

Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 6 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2026
First posted
May 22, 2026
StartEst.
May 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07601698
Lead sponsor
Sohag University
Responsible party
Taher Mohamed Aboelyamin (Resident of Anesthesiology, Surgical ICU and Pain Medicine, Sohag University) — Principal investigator
First posted
May 22, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 22, 2026

Study contacts

taher mohamed, residant
Contact
taher2014mohamed@yahoo.com
01120799228
elhadad ali mousa, professor
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Propofol

Start the discussion